Literature DB >> 10478810

Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone.

Y Hamada1, K Kawachi, T Yamamoto, T Nakata, Y Kashu, M Sato, Y Watanabe.   

Abstract

The effects of phosphodiesterase III (PDE III) inhibitors administered after aortic declamping during cardiopulmonary bypass (CPB) for open heart surgery were investigated. Ten patients (group M) were administered milrinone (50 microg/kg) after aortic declamping during CPB, 10 patients were administered amrinone (1 mg/kg) at the same time during their surgery (group A), and 10 patients served as controls with no drug administered (group C). Soon after bolus infusion of the PDE III inhibitor, perfusion pressure dropped significantly in groups M and A. However, after release of CPB and at the end of surgery, there was no difference in aortic pressure between the 3 groups. There were also no differences between the groups in heart rate, pulmonary artery pressure, and pulmonary capillary wedge pressure. After weaning from CPB, the cardiac index was high and systemic vascular resistance index was low in groups M and A. There were no significant differences in the need for additional catecholamines and time for rewarming between groups. No adverse reactions were observed. A single administration of a PDE III inhibitor during CPB was useful for post-CPB management of patients undergoing open heart surgery. Amrinone reduced perfusion pressures more than milrinone, but cardiac indices and aortic pressures after weaning from CPB showed no differences between group M and group A patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478810     DOI: 10.1253/jcj.63.605

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  2 in total

1.  The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis.

Authors:  Yu-Shan Ren; Lan-Fang Li; Tao Peng; Yu-Jun Tan; Ying Sun; Guo-Liang Cheng; Gui-Min Zhang; Jie Li
Journal:  BMC Cardiovasc Disord       Date:  2020-07-08       Impact factor: 2.298

2.  Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.

Authors:  Liping Sun; Haitian Quan; Chengying Xie; Lei Wang; Youhong Hu; Liguang Lou
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.